513 related articles for article (PubMed ID: 25860213)
1. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice.
Lee IC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lin HC; Lee FY; Huang YH
Medicine (Baltimore); 2015 Apr; 94(14):e688. PubMed ID: 25860213
[TBL] [Abstract][Full Text] [Related]
2. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
Lee PC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lee MH; Hou MC; Lee FY; Lin HC; Huang YH
Liver Int; 2018 Feb; 38(2):321-330. PubMed ID: 28736952
[TBL] [Abstract][Full Text] [Related]
3. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design.
Reig M; Rimola J; Torres F; Darnell A; Rodriguez-Lope C; Forner A; Llarch N; Ríos J; Ayuso C; Bruix J
Hepatology; 2013 Dec; 58(6):2023-31. PubMed ID: 23787822
[TBL] [Abstract][Full Text] [Related]
4. The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.
Wada Y; Takami Y; Tateishi M; Ryu T; Mikagi K; Saitsu H
PLoS One; 2016; 11(1):e0146456. PubMed ID: 26745625
[TBL] [Abstract][Full Text] [Related]
5. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
[TBL] [Abstract][Full Text] [Related]
6. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
[TBL] [Abstract][Full Text] [Related]
7. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study.
Fu SR; Zhang YQ; Li Y; Hu BS; He X; Huang JW; Zhan MX; Lu LG; Li JP
Asian Pac J Cancer Prev; 2014; 15(7):3151-6. PubMed ID: 24815462
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
[TBL] [Abstract][Full Text] [Related]
11. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
Kuo YH; Wang JH; Hung CH; Rau KM; Wu IP; Chen CH; Kee KM; Hu TH; Lu SN
J Gastroenterol Hepatol; 2017 Dec; 32(12):1975-1981. PubMed ID: 28295594
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
[TBL] [Abstract][Full Text] [Related]
13. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
Cho HJ; Kim SS; Nam JS; Oh MJ; Kang DR; Kim JK; Lee JH; Kim B; Yang MJ; Hwang JC; Lim SG; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
Cytokine; 2017 Jul; 95():118-125. PubMed ID: 28260649
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment.
Kuzuya T; Ishigami M; Ishizu Y; Honda T; Hayashi K; Ishikawa T; Nakano I; Hirooka Y; Goto H
Oncology; 2018; 95(2):91-99. PubMed ID: 29723866
[TBL] [Abstract][Full Text] [Related]
15. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function.
Yang H; Woo HY; Lee SK; Han JW; Jang B; Nam HC; Lee HL; Lee SW; Song DS; Song MJ; Oh JS; Chun HJ; Jang JW; Lozada A; Bae SH; Choi JY; Yoon SK
Clin Mol Hepatol; 2017 Jun; 23(2):128-137. PubMed ID: 28494528
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.
Pressiani T; Boni C; Rimassa L; Labianca R; Fagiuoli S; Salvagni S; Ferrari D; Cortesi E; Porta C; Mucciarini C; Latini L; Carnaghi C; Banzi M; Fanello S; De Giorgio M; Lutman FR; Torzilli G; Tommasini MA; Ceriani R; Covini G; Tronconi MC; Giordano L; Locopo N; Naimo S; Santoro A
Ann Oncol; 2013 Feb; 24(2):406-411. PubMed ID: 23041587
[TBL] [Abstract][Full Text] [Related]
18. Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib.
Yoo JJ; Chung GE; Lee JH; Nam JY; Chang Y; Lee JM; Lee DH; Kim HY; Cho EJ; Yu SJ; Kim YJ; Yoon JH;
Cancer Res Treat; 2018 Apr; 50(2):366-373. PubMed ID: 28521494
[TBL] [Abstract][Full Text] [Related]
19. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit.
King J; Palmer DH; Johnson P; Ross P; Hubner RA; Sumpter K; Darby S; Braconi C; Iwuji C; Swinson D; Collins P; Patel K; Nobes J; Muazzam I; Blesing C; Kirkwood A; Nash S; Meyer T
Clin Oncol (R Coll Radiol); 2017 Apr; 29(4):256-262. PubMed ID: 27964898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
